Paul Dennis Miller
#124,187
Most Influential Person Now
Researcher
Paul Dennis Miller's AcademicInfluence.com Rankings
Paul Dennis Millerengineering Degrees
Engineering
#4022
World Rank
#5178
Historical Rank
Electrical Engineering
#984
World Rank
#1059
Historical Rank
Paul Dennis Millercomputer-science Degrees
Computer Science
#5130
World Rank
#5420
Historical Rank
Data Science
#78
World Rank
#80
Historical Rank
Computational Linguistics
#642
World Rank
#654
Historical Rank
Machine Learning
#1244
World Rank
#1264
Historical Rank
Download Badge
Engineering Computer Science
Paul Dennis Miller's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Mathematics University of California, Berkeley
Similar Degrees You Can Earn
Why Is Paul Dennis Miller Influential?
(Suggest an Edit or Addition)Paul Dennis Miller's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. (1999) (2436)
- Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. (2001) (1551)
- Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. (2001) (1204)
- Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. (1990) (949)
- Denosumab in postmenopausal women with low bone mineral density. (2006) (933)
- Alendronate for the treatment of osteoporosis in men. (2000) (858)
- Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism (2009) (802)
- Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis (1999) (739)
- Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. (2005) (668)
- Bone mineral density thresholds for pharmacological intervention to prevent fractures. (2004) (558)
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. (2016) (543)
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. (2008) (508)
- Osteoporosis and Fracture Risk in Women of Different Ethnic Groups (2004) (498)
- Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. (2002) (479)
- Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. (2011) (474)
- Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures (2004) (449)
- Antifracture efficacy of antiresorptive agents are related to changes in bone density. (2000) (411)
- Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. (2013) (408)
- Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. (2005) (403)
- Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. (2005) (397)
- Discordance in patient classification using T-scores. (1999) (390)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. (2020) (361)
- Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. (1993) (353)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. (2016) (349)
- Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions. (2008) (342)
- A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. (2002) (324)
- Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1‐Year Results From the MOBILE Study (2005) (323)
- Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study (2005) (323)
- Prediction of Fracture Risk in Postmenopausal White Women With Peripheral Bone Densitometry: Evidence From the National Osteoporosis Risk Assessment (2002) (320)
- Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD (2007) (311)
- A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. (2007) (308)
- Effects of denosumab on fracture and bone mineral density by level of kidney function (2011) (301)
- Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis (2011) (289)
- Importance of precision in bone density measurements. (2001) (256)
- The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA) (2006) (253)
- Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women (1993) (251)
- Benefits and risks of bisphosphonate therapy for osteoporosis. (2012) (235)
- Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2‐Yr Results of a Randomized, Double‐Blind, Placebo‐, and Active‐Controlled Study (2007) (227)
- Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies (2010) (224)
- Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure (2007) (214)
- National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. (2008) (203)
- Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment (2006) (199)
- Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. (2008) (191)
- Vertebral Fractures: Clinical Importance and Management. (2016) (189)
- A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone (1999) (179)
- A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. (2012) (177)
- Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. (2004) (165)
- A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis (2018) (164)
- Bone mineral density in elite junior Olympic weightlifters. (1993) (164)
- Change in Lumbar Spine BMD and Vertebral Fracture Risk Reduction in Teriparatide‐Treated Postmenopausal Women With Osteoporosis (2006) (162)
- Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates (2016) (161)
- Observations following discontinuation of long-term denosumab therapy (2017) (160)
- Bone densitometry: the best way to detect osteoporosis and to monitor therapy. (1999) (155)
- Efficacy and safety of a once‐yearly i.v. Infusion of zoledronic acid 5 mg versus a once‐weekly 70‐mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double‐blind, active‐controlled study (2010) (154)
- Long‐Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate (2006) (147)
- Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. (1997) (145)
- Diagnosis and Management of Osteoporosis: Guidelines for the Utilization of Bone Densitometry (1997) (144)
- Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies* (2008) (140)
- Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. (2006) (140)
- Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. (1999) (139)
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. (2011) (136)
- Pathogenic mechanisms in early norepinephrine-induced acute renal failure: functional and histological correlates of protection. (1978) (135)
- The kidney and bisphosphonates. (2011) (132)
- Perspective: Assessing the Clinical Utility of Serum CTX in Postmenopausal Osteoporosis and Its Use in Predicting Risk of Osteonecrosis of the Jaw (2009) (131)
- Predictive Value of Low BMD for 1‐Year Fracture Outcomes Is Similar for Postmenopausal Women Ages 50‐64 and 65 and Older: Results From the National Osteoporosis Risk Assessment (NORA) (2004) (126)
- Alendronate Improves Bone Mineral Density in Elderly Women with Osteoporosis Residing in Long-Term Care Facilities (2002) (126)
- Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA) (2009) (125)
- An approach to identifying osteopenic women at increased short-term risk of fracture. (2004) (123)
- PINP as a biological response marker during teriparatide treatment for osteoporosis (2014) (123)
- Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. (2008) (118)
- Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. (2004) (117)
- Recalculation of the NHANES Database SD Improves T‐Score Agreement and Reduces Osteoporosis Prevalence (2004) (115)
- Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data (2009) (115)
- Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. (2006) (114)
- A single infusion of zoledronic acid produces sustained remissions in paget disease: Data to 6.5 years (2011) (111)
- Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial (2017) (109)
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial (2012) (109)
- ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis (2018) (107)
- Secondary and tertiary hyperparathyroidism. (2013) (106)
- Hypodipsia in geriatric patients. (1982) (103)
- Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE (2005) (102)
- Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long‐term continuation on bone turnover and fracture risk—a perspective (2012) (101)
- RANKL Inhibition With Denosumab Does Not Influence 3‐Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk (2014) (100)
- A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. (2015) (98)
- Safety of bisphosphonates in the treatment of osteoporosis. (2009) (98)
- Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. (1980) (96)
- Renal safety in patients treated with bisphosphonates for osteoporosis: A review (2013) (96)
- Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: Results from the national osteoporosis risk assessment (2002) (95)
- Bone disease in CKD: a focus on osteoporosis diagnosis and management. (2014) (94)
- What are the standards by which bone mass measurement at peripheral skeletal sites should be used in the diagnosis of osteoporosis? (2002) (93)
- Management of severe osteoporosis (2016) (93)
- Rapid Loss of Hip Fracture Protection After Estrogen Cessation: Evidence From the National Osteoporosis Risk Assessment (2004) (93)
- Denosumab: Anti-RANKL antibody (2009) (90)
- Fracture risk assessment in patients with chronic kidney disease (2012) (88)
- Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. (1994) (87)
- Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA) (2008) (86)
- Comparison of BMD precision for Prodigy and Delphi spine and femur scans (2006) (85)
- Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry. (1996) (83)
- Pharmacokinetics of Teriparatide (rhPTH[1–34]) and Calcium Pharmacodynamics in Postmenopausal Women with Osteoporosis (2010) (81)
- Guidelines for the diagnosis of osteoporosis: T-scores vs fractures (2007) (80)
- Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study (2008) (79)
- Increases in BMD Correlate With Improvements in Bone Microarchitecture With Teriparatide Treatment in Postmenopausal Women With Osteoporosis (2007) (78)
- 2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. (2013) (77)
- Is There a Role for Bisphosphonates in Chronic Kidney Disease? (2007) (77)
- Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years (2015) (76)
- Effects of furosemide and acetylcholine in norepinephrine-induced acute renal failure. (1978) (75)
- The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements? (1998) (74)
- How useful are measures of BMD and bone turnover?* (2005) (73)
- Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population (1996) (73)
- Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. (2013) (73)
- Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. (2012) (73)
- Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study (2003) (72)
- Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction (2005) (71)
- Executive summary International Society for Clinical Densitometry position development conference Denver, Colorado July 20-22, 2001. (2002) (69)
- Treatment of osteoporosis in chronic kidney disease and end-stage renal disease (2005) (68)
- Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis (2009) (67)
- Treatment of alcoholic acidosis: the role of dextrose and phosphorus. (1978) (66)
- Diagnosis and treatment of osteoporosis in chronic renal disease. (2009) (66)
- Role of the renin-angiotensin system in post-transplantation hypertension in patients with multiple kidneys. (1978) (65)
- A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis (2011) (63)
- Underdiagnosis and Undertreatment of Osteoporosis: The Battle to Be Won. (2016) (62)
- Clinical Value of Monitoring BMD in Patients Treated With Bisphosphonates for Osteoporosis (2009) (61)
- Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker (2008) (61)
- The role of bone biopsy in patients with chronic renal failure. (2008) (60)
- Bisphosphonates and bone quality. (2014) (60)
- Safety of parathyroid hormone for the treatment of osteoporosis (2008) (59)
- Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. (2007) (58)
- Responses to Treatment With Teriparatide in Patients With Atypical Femur Fractures Previously Treated With Bisphosphonates (2017) (56)
- Burosumab for the Treatment of Tumor‐Induced Osteomalacia (2020) (54)
- An approach for identifying postmenopausal women age 50–64 years at increased short-term risk for osteoporotic fracture (2007) (54)
- Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. (1994) (52)
- Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension (2014) (52)
- RENAL CELL CARCINOMA: UNUSUAL SYSTEMIC MANIFESTATIONS (1976) (51)
- Comparative effect of diuretics on renal water excretion in hyponatraemic oedematous disorders. (1982) (51)
- Chronic kidney disease and osteoporosis: evaluation and management. (2014) (50)
- Anti-resorptives in the management of osteoporosis. (2008) (50)
- Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. (2008) (50)
- Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study. (2016) (50)
- Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. (2005) (49)
- Use of the ASI titanium stent in the management of bladder outflow obstruction due to benign prostatic hyperplasia. (1992) (49)
- A novel transurethral microwave thermal ablation system to treat benign prostatic hyperplasia: results of a prospective multicenter clinical trial. (1997) (49)
- Remodeling‐ and Modeling‐Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study (2018) (48)
- A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. (1999) (47)
- Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. (2011) (47)
- Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. (2000) (47)
- Standards for performing DXA in individuals with secondary causes of osteoporosis. (2006) (46)
- Bone densitometry in asymptomatic primary hyperparathyroidism. (2002) (46)
- Polyuric prerenal failure. (1980) (46)
- Renal safety of intravenous bisphosphonates in the treatment of osteoporosis (2007) (46)
- Design of NORA, the National Osteoporosis Risk Assessment Program: a longitudinal US registry of postmenopausal women. (1998) (44)
- Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet (2011) (44)
- A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial (2016) (44)
- Fragility fractures in chronic kidney disease: An opinion-based approach (2009) (43)
- Controversies in Bone Mineral Density Diagnostic Classifications (2000) (43)
- Chronic kidney disease and the skeleton (2014) (42)
- DXA-generated Z-scores and T-scores may differ substantially and significantly in young adults. (2007) (42)
- More bone density testing is needed, not less (2012) (42)
- Prediction of fracture risk. I: Bone density. (1996) (42)
- Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. (2000) (42)
- Clinical Performance of a Highly Portable, Scanning Calcaneal Ultrasonometer (2001) (42)
- Hormonal control of renal water excretion. (1976) (40)
- A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate (2006) (39)
- Standards and guidelines for performing central dual X-ray densitometry from the Canadian Panel of International Society for Clinical Densitometry. (2002) (39)
- What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? (2010) (38)
- Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. (2005) (38)
- Encrustation of intraprostatic stents--a comparative study. (1992) (37)
- Clinical use of teriparatide in the real world: initial insights. (2004) (37)
- Acute metabolic alkalosis perpetuating hypercarbia. A role for acetazolamide in chronic obstructive pulmonary disease. (1977) (37)
- Bisphosphonate-associated atypical sub-trochanteric femur fractures: paired bone biopsy quantitative histomorphometry before and after teriparatide administration. (2015) (33)
- Bone and Kidney Disease: Diagnostic and Therapeutic Implications (2012) (33)
- Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report. (2015) (32)
- Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength. (2014) (32)
- Weekly Oral Alendronic Acid in Male Osteoporosis (2004) (32)
- Central, renal and adrenal effects of lithium in man. (1979) (32)
- The 2002 Canadian bone densitometry recommendations: take-home messages. (2002) (31)
- Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial. (2019) (30)
- Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate (2010) (30)
- Vertebral Fracture Risk Is Reduced in Women Who Lose Femoral Neck BMD With Teriparatide Treatment (2009) (30)
- Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study (2016) (30)
- Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics. (2021) (29)
- Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. (2005) (29)
- Uses and misuses of quantitative ultrasonography in managing osteoporosis. (2006) (29)
- Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. (2009) (29)
- Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies (2013) (28)
- Position Development Conference (2003) (28)
- Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis (2018) (28)
- Risedronate reduces hip fractures in patients with low femoral neck bone mineral density (1999) (27)
- Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease (2020) (27)
- Fracture Healing in Two Adult Patients With Hypophosphatasia After Asfotase Alfa Therapy (2018) (27)
- Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial (2019) (27)
- Tolerability of risedronate in postmenopausal women intolerant of alendronate (2001) (27)
- Monitoring osteoporosis therapies (2007) (26)
- Bisphosphonates for the Prevention and Treatment of Corticosteroid-Induced Osteoporosis (2001) (26)
- Cooled thermotherapy for the treatment of benign prostatic hyperplasia: durability of results obtained with the Targis System. (2003) (26)
- Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study. (2011) (26)
- Clinical Application of Bone Densitometry (1998) (26)
- Hypocalciuric effect of lithium in man. (1977) (25)
- Improved precision with Hologic Apex software (2008) (25)
- Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis (2003) (25)
- Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study (2020) (25)
- 2008 Santa Fe Bone Symposium: update on osteoporosis. (2009) (25)
- Unrecognized and unappreciated secondary causes of osteoporosis. (2012) (24)
- Osteoporosis update from the 2010 santa fe bone symposium. (2011) (24)
- Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates (2019) (24)
- Rib fracture as a predictor of future fractures in young and older postmenopausal women: National Osteoporosis Risk Assessment (NORA) (2012) (23)
- Management of osteoporosis. (1999) (22)
- Bone mineral density--clinical use and application. (2003) (22)
- The effect of potassium loading on sodium excretion and plasma renin activity in Addisonian man. (1975) (22)
- Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease (2020) (22)
- Transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia: results obtained with the Urologix T3 device (1998) (20)
- Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study (2007) (20)
- Hypotensive sequelae of diazoxide and hydralazine therapy. (1977) (20)
- Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data (2008) (20)
- Traumatic renal artery thrombosis. (1986) (20)
- FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. (2011) (19)
- Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. (2014) (19)
- Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. (2008) (19)
- Analysis of 1-year Vertebral Fracture Risk Reduction Data in Treatments for Osteoporosis (2003) (18)
- Rationale, objectives and design of the Direct Analysis of Nonvertebral Fracture in the Community Experience (DANCE) Study (2005) (18)
- Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. (2017) (18)
- Dual-energy X-ray absorptiometry diagnostic discordance between Z-scores and T-scores in young adults. (2009) (17)
- 2009 Santa Fe Bone symposium. (2010) (16)
- Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group (2019) (16)
- Osteoporosis update: proceedings of the 2013 Santa Fe Bone Symposium. (2014) (16)
- Further Nonvertebral Fracture Reduction Beyond 3 Years for up to 10 Years of Denosumab Treatment. (2019) (16)
- Guidelines for the clinical utilization of bone mass measurement in the adult population (1995) (16)
- Bone strength and surrogate markers: The first, second, and third fiddle (2012) (16)
- Osteoporosis update from the 2012 Santa Fe Bone Symposium. (2013) (15)
- Response to "The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry," by John A. Kanis et al. (2005) (15)
- Fracture incidence in a large cohort of men age 30 years and older with osteoporosis (2015) (14)
- Bone mass measurements. (2003) (14)
- Effects of ospemifene on bone parameters including clinical biomarkers in postmenopausal women (2016) (14)
- Proceedings of the Eighth Annual Santa Fe Bone Symposium, August 3-4, 2007. (2008) (14)
- Diagnostic agreement at the total hip using different DXA systems and the NHANES III database. (2007) (14)
- Eosinophilic prostatitis and prostatic specific antigen. (1992) (14)
- The history of bone densitometry. (2017) (14)
- Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis (2013) (13)
- Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis (2021) (13)
- Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. (2019) (13)
- Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBDs): What the Endocrinologist Needs to Know. (2014) (13)
- Update on osteoporosis from the 2014 Santa Fe Bone symposium (2015) (13)
- History of etidronate. (2020) (12)
- Current Understanding of Mineral and Bone Disorders of Chronic Kidney Disease and the Scientific Grounds on the Use of Exogenous Parathyroid Hormone in Its Management (2020) (12)
- Treatment of metabolic bone disease in patients with chronic renal disease: A perspective for rheumatologists (2005) (12)
- Proceedings of the 2011 Santa Fe Bone symposium. (2012) (12)
- The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. (2010) (12)
- Vitamin D, calcium, and cardiovascular mortality: a perspective from a plenary lecture given at the annual meeting of the American Association of Clinical Endocrinologists. (2011) (12)
- New or worsening lumbar spine vertebral fractures increase lumbar spine bone mineral density and falsely suggest improved skeletal status. (2006) (12)
- Controversial Issues in Bone Densitometry (2002) (11)
- Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: Is treatment with bisphosphonates an option? (2014) (11)
- Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis. (2018) (11)
- A comparative trial of risedronate vs. etidronate in the treatment of patients with Paget’s disease of bone (1999) (11)
- Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide (2017) (11)
- OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome (2019) (10)
- Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases. (2017) (10)
- Bone Mass Measurements The Case for Selected Screening? (1997) (10)
- Proceedings of the 2015 Santa Fe Bone Symposium: Clinical Applications of Scientific Advances in Osteoporosis and Metabolic Bone Disease. (2016) (9)
- Management of erections during transurethral surgery using ethyl chloride spray. (1993) (9)
- Balloon dilatation of the prostate--should it have a place in the urologist's armamentarium? (1993) (9)
- Preferential heating using transurethral thermoablation (T3) improves clinical results (1997) (9)
- Long-term efficacy of zoledronic acid compared with risedronate in Paget's disease (2010) (9)
- Use of lowest single lumbar spine vertebra bone mineral density T-score and other T-score approaches for diagnosing osteoporosis and relationships with vertebral fracture status. (2008) (9)
- Cyclical etidronate treatment of postmenopausal osteoporosis: 4 year experience (1992) (8)
- The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function (2010) (8)
- Effects of once-yearly zoledronic acid 5 mg in combination with teriparatide (PTH) on postmenopausal women with osteoporosis (2010) (8)
- Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis (2020) (8)
- Bone Density Testing: Science, the Media, and Patient Care (2014) (8)
- Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone Diseases. (2019) (8)
- Hypomagnesemia. Suppression of secondary hyperparathyroidism in chronic renal failure. (1979) (7)
- Seven years of cyclical etidronate: Continued improvement in spine bmd and progressive decline in vertebral fracture incidence (1995) (7)
- Clinical Management of Vertebral Compression Fractures. (2016) (7)
- Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis. (2019) (7)
- Distinction between the common symptoms of the phosphate-depletion syndrome and glucocorticoid-induced disease. (1978) (7)
- Effect of cyclical therapy with phosphorus and etidronate on axial bone mineral density in postmenopausal osteoporotic women (1991) (6)
- Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density (2021) (6)
- Response to “The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry” by John A. Kanis et al. (2005) (6)
- Role of Solute Excretion in Prevention of Norepinephrine-Induced Acute Renal Failure (1978) (6)
- Osteoporosis: A Guide for Clinicians (2007) (6)
- Pitfalls in bone mineral density measurements (2004) (5)
- The Osteoporosis Primer: Bone mineral density measurements (2000) (5)
- Further reduction in nonvertebral fracture rate is observed following 3 years of denosumab treatment: results with up to 7 years in the freedom extension (2014) (5)
- The treatment of osteoporosis. Antiresorptive therapy. (2000) (5)
- 26 – Renal Bone Diseases (2005) (5)
- Management of osteoporosis. (1999) (4)
- Denosumab (AMG 162) Inhibition of Rank Ligand Increases Bone Mineral Density After Two Years of Treatment in Postmenopausal Women with Low Bone Mineral Density (2006) (4)
- Proceedings of the 2021 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis and Metabolic Bone Diseases. (2021) (4)
- Greater Risk, Greater Benefit—True or False? (2003) (4)
- RENAL EFFECTS OF TREATMENT WITH ZOLEDRONIC ACID: RESULTS FROM THE HORIZON-PFT EXTENSION STUDY (2012) (4)
- All bisphosphonates are (or may not be) the same: potential reasons for clinical differences. (2010) (4)
- Four-year Results of a Phase 2 Study of the Cathepsin K Inhibitor Odanacatib in Postmenopausal Women with Low Bone Mineral Density: Effects on Bone Mineral Density and Bone Turnover Markers (2011) (4)
- Skeletal health and bone strength: DXA and beyond growth for the Journal of Clinical Densitometry. (2008) (4)
- The use of risedronate in Paget's disease. (1999) (4)
- BMD Response to Delayed-Release Risedronate 35 Mg Once-A-Week Formulation Taken With or Without Breakfast (2010) (4)
- A randomized double-blind study of Denosumab (DMAB) compared with Zoledronic acid (ZOL) in postmenopausal women with osteoporosis previously treated with oral bisphosphonates (2016) (3)
- Benign Prostatic Hyperplasia: Laser and Heat Therapy (2001) (3)
- The role of osteoanabolic agents in the management of patients with osteoporosis (2022) (3)
- Author response for "Burosumab for the Treatment of Tumor-Induced Osteomalacia" (2020) (3)
- Presidential Message: Journal of Clinical Densitometry (1998) (3)
- Effects of arzoxifene on fracture incidence in postmenopausal women with osteoporosis or with low bone mass (2010) (3)
- Bone histomorphometry after long-term treatment with cyclical phosphorus and etidronate (1992) (3)
- Intermittent cyclical etidronate treatment of postmenopausal osteoporosis : New Engl. J. Med. 1990 323/2 (73–79) (1991) (3)
- Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend (2019) (3)
- Bone Density Testing Is the Best Way to Monitor Osteoporosis Treatment. (2017) (3)
- New possibilities for diagnosis and treatment of osteoporosis. (2001) (3)
- Determinants of Bone Strength (2003) (3)
- Vertebral Fracture Risk Is Reduced for Women Who Lose Femoral Neck Bone Mineral Density During Teriparatide Treatment (2008) (3)
- Estimation of Long‐Term Efficacy of Denosumab Treatment in Postmenopausal Women With Osteoporosis: A FRAX‐ and Virtual Twin‐Based Post Hoc Analysis From the FREEDOM and FREEDOM Extension Trials (2020) (3)
- Management of Osteoporosis in Patients with Chronic Kidney Disease (2018) (2)
- Chapter 89 – Controversial Issues in Bone Densitometry (2008) (2)
- The CKD‐MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management (2020) (2)
- The impact of subject demographics on young adult DXA Z-scores (2007) (2)
- A phase 3 study of the efficacy and safety of Denosumab in men with low bone mineral density : design of the ADAMO (2011) (2)
- Clinical Use of Bone Densitometry (2013) (2)
- Monthly oral ibandronate is at least as effective as daily oral ibandronate: 1-year results from MOBILE (2005) (2)
- Bone Densitometry in the Elderly (2000) (2)
- Six-Year Safety and Efficacy Data from Denosumab Phase 2 Extension Study (2010) (2)
- Risedronate demonstrates fracture efficacy in postmenopausal women whether there is a BMD gain or loss during treatment (2006) (2)
- 95 – The Clinical Application of Gender-Based Databases for the Diagnosis of Osteoporosis and Fracture Risk Prediction (2004) (2)
- Simple Test for Hypercalciuria (1975) (2)
- Changing perceptions in osteoporosis. Markers should be used as adjunct to bone densitometry. (1999) (2)
- Meeting report from the 24th annual meeting of the American society for bone and mineral research (2002) (2)
- Editorial: greater risk, greater benefit--true or false? (2003) (2)
- Combination therapy for osteoporosis: parathyroid hormone and bisphosphonates (2004) (2)
- Suppression of Secondary Hyperparathyroidism in Chronic Renal Failure (2016) (2)
- TBS Precision and Comparison between the Hologic and GE-Lunar DXA Scanners (2015) (2)
- Bone Mineral Density in Chronic Kidney Disease Use and Misuse (2012) (2)
- 459 BONE MINERAL DENSITY IN ELITE JUNIOR WEIGHTLIFTERS (1990) (2)
- CHRONIC KIDNEY DISEASE MINERAL AND BONE DISORDERS (CKD-MBD) WHAT THE ENDOCRINOLOGIST NEEDS TO KNOW Running title: CKD-MBD and Endocrinologists (2013) (2)
- Continuation of Bisphosphonate Therapy for Osteoporosis beyond 5 Years. (2022) (2)
- Denosumab (DMab) restores cortical bone loss at the 1/3 radius associated with ageing and reduces wrist fracture risk: analyses from the FREEDOM Extension Cross-over Group (2015) (2)
- A single dose of zoledronic acid 5 mg achieves more sustained biochemical remission versus daily 30mg risedronate in patients with Paget's disease (2006) (2)
- Cooled thermotherapy (TUMT) for chronic abacterial prostatitis (CP/CPPS): 2 years after treatment (2005) (1)
- Osteoporosis: An Overview (2018) (1)
- Rehabilitation of Patients with fRagility-Related fRactuRes (2014) (1)
- Intravenous bisphosphonate safety: The realities (2007) (1)
- Urethroplasty for condylomata acuminata throughout the urethra. (1992) (1)
- Efficacy and adverse event profile of monthly oral ibandronate during the first year of the mobile long-term extension study (2007) (1)
- Standard Techniques of Bone Mass Measurement in Adults (2018) (1)
- CHAPTER 62 – Clinical Use of Bone Densitometry (2008) (1)
- Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. (2004) (1)
- The use of teriparatide and PTH(1–84) for the treatment of osteoporosis (2006) (1)
- Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing (2021) (1)
- BONE BIOPSY ANALYSIS DETECTS METABOLIC BONE DISEASE IN FEMALE RUNNERS.: 683 (1980) (1)
- Treatment with Abaloparatide Significantly Reduces Wrist Fractures Compared to Teriparatide - Results of the Phase 3 ACTIVE Trial (2015) (1)
- A pooled analysis demonstrates IV ibandronate injection is associated with a favorable renal safety profile (2007) (1)
- Prevention and management of osteoporosis. (2003) (1)
- Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases (2018) (1)
- “Evidence-based” or “logic-based” medicine? (2010) (1)
- Erratum: Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long‐term continuation on bone turnover and fracture risk—A perspective (2012) (1)
- An Approach to Identifying Osteopenic Women at Increased Short-term Risk of Fracture (2004) (1)
- Meeting report from the IOF world congress on osteoporosis (2002) (1)
- Bone histology and histomorphometry: effects of 5 years of denosumab in the FREEDOM Extension (2013) (1)
- Should low bone mass be treated? (2005) (1)
- Relationship between changes in bone mineral density and incidence of fracture with 6 years of Denosumab treatment (2012) (1)
- Chapter 20 – Combination Therapy for Osteoporosis: What Do the Data Show Us? (2006) (1)
- Defining strategies for improving the identification and management of osteoporosis in the primary care setting. (2003) (1)
- Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women (2017) (1)
- A randomized double-blind study of denosumab compared with zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonate. (2015) (1)
- OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome (2020) (1)
- Long-term extension trials to prove the efficacy and safety of bisphosphonates (2014) (1)
- Management of Fractures in Men with Impaired Renal Function (2010) (0)
- Osteoporosis awareness in 1994. (1994) (0)
- Relationship Between Baseline Bone Turnover Marker Levels and Bone Mineral Density Changes in Men with Low Bone Mineral Density Receiving Denosumab or Placebo (2012) (0)
- 379Cooled thermotherapy (TUMT) for chronic abacterial prostatitis — 2 years after treatment (2005) (0)
- Author response for "Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women with Osteoporosis" (2020) (0)
- Sustained Reduction of Bone Turnover Markers throughout the Time-Interval between Weekly Doses of Alendronate or Risedronate (2006) (0)
- Bone Mass Measurement (2004) (0)
- Effects of denosumab on structural geometry of the proximal femur in postmenopausal women with low bone mass as determined by hip structural analysis (2007) (0)
- Bone Mass Measurement Techniques in Clinical Practice (2000) (0)
- Update on Rationale and Development of New Agents for the Treatment of Osteoporosis (2010) (0)
- In Memoriam: Sergio Ragi-Eis, MD, CCD, CDT (April 8, 1962–February 22, 2012). (2012) (0)
- The influence of denosumab on one mineral densityand biochemical markers of bone remodeling: results of 6-year phase ii trial (2011) (0)
- Suppression of Bone-Turnover Markers at 3 months is Maintained at 2 Years with Once-Monthly Ibandronate: MOBILE 2-Year Data (2006) (0)
- Erratum: Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long‐term continuation on bone turnover and fracture risk—A perspective (2012) (0)
- Proceedings of the 2022 Santa Fe Bone Symposium: Current Concepts in the Care of Patients with Osteoporosis and Metabolic Bone Diseases. (2022) (0)
- Reply to Letter to the Editor: Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease (2023) (0)
- Taxonomy of rare genetic metabolic bone disorders (vol 26, pg 2529, 2015) (2015) (0)
- Betsy McClung 1942–2015 (2015) (0)
- Erratum to: Prevalence of renal impairment among osteoporotic women in the USA, NHANES 2005–2008: is treatment with bisphosphonates an option? (2014) (0)
- Bisphosphonates pharmacology and use in the treatment of osteoporosis (2021) (0)
- The protective and reversal effects of high dose furosemide (F) in norepinephrine (NE) induced acute renal failure (ARF) (1976) (0)
- Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study (2020) (0)
- Benefits and risks of bisphosphonate therapy for osteoporosis: Editorial comment (2013) (0)
- Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed by 24 Months of Alendronate (2018) (0)
- Hypercalcemia: Diagnosis and Treatment (2002) (0)
- Fragility fractures in chronic kidney disease: A clarification of views. Author's reply (2010) (0)
- Letter: Phosphorus restriction and vitamin D metabolism. (1973) (0)
- Protective Effects of Estrogen on BMD Erode After Discontinuation: P-54. (1999) (0)
- List of contributors (2021) (0)
- ZOLEDRONOVAYa KISLOTA V PROFILAKTIKE POTERI KOSTNOY TKANI U zhENShchIN POSTMENOPAUZAL'NOGO VOZRASTA S OSTEOPENIEY (2011) (0)
- Qualifications for densitometry technologists: a position statement. (1999) (0)
- Efficacy of Denosumab in Increasing Hip Bone Mineral Density in Older Versus Younger Women With Postmenopausal Osteoporosis (2012) (0)
- Clinical comparison in BMD gains with monthly oral ibandronate (150 mg) and weekly oral alendronate (70 mg) : results from the MOTION study (2007) (0)
- BMD Improvements in Postmenopausal Osteoporosis: MOBILE Shows Continued Superiority of Once-Monthly Ibandronate at 2 Years (2006) (0)
- The MOBILE study long-term extension: Progressive bone density gains with 150mg once-monthly oral ibandronate. (2006) (0)
- CHAPTER 74 – Bisphosphonates: Pharmacology and Use in the Treatment of Osteoporosis (2008) (0)
- Efficacy and Safety of Monthly Oral Ibandronate In Postmenopausal Women With Osteopenia (2008) (0)
- Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide (2018) (0)
- rti , . : ll ' Secondary and Tertiary Hyperparathyroidism (2017) (0)
- Bone Mass in Renal Disease (1996) (0)
- The Effects of 8 Years of Continuous Denosumab Treatment on Bone Mineral Density and Biochemical Markers of Bone Turnover in a Phase 2 Study (2012) (0)
- Effects of risedronate on risk of femoral neck and intertrochanteric fractures (2002) (0)
- TBS precision and accuracy comparison between the hologic and GE-lunar DXA systems (2014) (0)
- Osteoporosis: Guidelines for Management: P-63. (1996) (0)
- Parathyroid dysfunction in renal disease (1996) (0)
- Prediction of vertebral fracture incidence from baseline fractures and bone mass (1992) (0)
- The rechallenge of patients who previously discontinued alendronate due to upper gastrointestinal symptoms (2000) (0)
- MOBILE 2-Year: Efficacy and Tolerability of Once-Monthly Ibandronate in Postmenopausal Osteoporosis (2006) (0)
- Letter to the editor (1994) (0)
- Denosumab for the treatment of men with low bone mineral density: 24-month results from the Adamo Trial (2014) (0)
- Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide (2017) (0)
- Bone densitometry and osteoporotic fracture risk. (1994) (0)
- Bones and the Kidney (2021) (0)
- Standards and guidelines for performing central dual X-ray densitometry from the Canadian panel of International Society for Clinical Densitometry. (2002) (0)
- Manpower and hours of work agreements are complementary. (1991) (0)
- Bone Density and Fracture Risk in Primary Hyperparathyroidism (2012) (0)
- Diseases of Mineral Metabolism and Bone: Emerging Therapeutics for Postmenopausal Osteoporosiss (2012) (0)
- Osteoporose-Update 1/2007 (2007) (0)
- Abstract #796012: Phase 1B Evaluation of the Pharmacokinetics and Pharmacodynamics of Abaloparatide Solid Microstructured Transdermal System in Postmenopausal Women with Low Bone Mineral Density (2020) (0)
- Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker: reply to Yarom and Elad (2008) (0)
- Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis (2020) (0)
- Use of lowest individual lumbar spine BMD T-score for diagnosis of osteoporosis and for prediction of prevalent and incident vertebral fractures (2007) (0)
- Long-term denosumab therapy further reduces the rate of non-vertebral fractures in women with persisting low hip BMD after 3 years (2014) (0)
- Once-monthly oral ibandronate a new bisphosphonate dosing concept (2004) (0)
- Precision assessment of the Hologic Apex software (2007) (0)
- Alendronate and Parathyroid Hormone (2005) (0)
- Expanding the list of etiologic factors for osteoporosis in men. (1997) (0)
- PMS79 PHASE 1B EVALUATION OF PATIENT EXPERIENCE WITH ABALOPARATIDE SOLID MICROSTRUCTURED TRANSDERMAL SYSTEM IN POSTMENOPAUSAL WOMEN WITH LOW BONE MINERAL DENSITY (2020) (0)
- Monthly ibandronate use is associated with a high percentage of BMD responders (2007) (0)
- Use and Misuse of Peripheral Bone Densitometry (2002) (0)
- [Renal osteodystrophy]. (1957) (0)
- Fracture Risk among Women with Discordance of BMD measurements at Hip and Spine: Evidence from National Osteoporosis Risk Assessment (NORA) (2006) (0)
- Response to the Letter: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid. (2016) (0)
- 33 Bone Mineral Density and Fracture Risk in Chronic Kidney Disease (2009) (0)
- Abstract #50: Back Pain in Women With Postmenopausal Osteoporosis Treated with Teriparatide 40 μg/day (TPTD40) or with Alendronate 10 mg/day (ALN10) (2004) (0)
- Fragility fractures in chronic kidney disease: A clarification of views (December 2009) (2010) (0)
- Utility of peripheral densitometry in assessment of patients in primary care (2001) (0)
- Bone AnABolic TherApy for osTeoporosis (0)
- ISCD Welcomes Elsevier to the Journal of Clinical Densitometry (2006) (0)
- Osteoporosis: Evaluation and Management (2000) (0)
- Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide (2018) (0)
- 205 – Renal osteodystrophy (2015) (0)
- Clinical Interpretation and Utility of Bone Densitometry (1996) (0)
- DENOSUMAB INCREASES TOTAL HIP BONE MINERAL DENSITY IN OLDER WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS (2012) (0)
- Osteoporosis Associated with Systemic Illness and Medications (2003) (0)
- Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis (2020) (0)
- COMPARATIVE EFFECTS OF SUBMAXIMAL CYCLING AND RUNNING ON URINARY PROTEIN EXCRETION: 634 (1980) (0)
- Can we use bone turnover markers as targets for antiresorptive treatment in postmenopausal osteoporosis ? an analysis from two phase 3 clinical trials. (2015) (0)
- Bone-density testing interval and transition to osteoporosis. (2012) (0)
- Clinical Skeletal Syndromes Associated with Parathyroid Disorders in Chronic Kidney Disease (2015) (0)
- RoleofSolute Excretion inPrevention ofNorepinephrine-Induced AcuteRenalFailure (1978) (0)
- Comparison of bone architecture via micro-ct after long-term treatment with risedronate and alendronate: A cross-sectional study in women with postmenopausal osteoporosis (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Paul Dennis Miller?
Paul Dennis Miller is affiliated with the following schools:
